Free Trial

Dyne Therapeutics (DYN) Competitors

Dyne Therapeutics logo
$14.41 -0.05 (-0.35%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$14.40 -0.01 (-0.03%)
As of 06/13/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DYN vs. LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, ADMA, PCVX, and AKRO

Should you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.

Dyne Therapeutics vs. Its Competitors

Dyne Therapeutics (NASDAQ:DYN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.

Dyne Therapeutics presently has a consensus price target of $44.93, suggesting a potential upside of 211.79%. Legend Biotech has a consensus price target of $76.20, suggesting a potential upside of 106.90%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than Legend Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
3.00
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91

Legend Biotech received 43 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 79.03% of users gave Dyne Therapeutics an outperform vote while only 73.02% of users gave Legend Biotech an outperform vote.

CompanyUnderperformOutperform
Dyne TherapeuticsOutperform Votes
49
79.03%
Underperform Votes
13
20.97%
Legend BiotechOutperform Votes
92
73.02%
Underperform Votes
34
26.98%

Dyne Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$235.94M-$3.59-4.01
Legend Biotech$728.30M9.29-$518.25M-$0.59-62.42

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 14.1% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Legend Biotech had 8 more articles in the media than Dyne Therapeutics. MarketBeat recorded 14 mentions for Legend Biotech and 6 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.03 beat Legend Biotech's score of 0.69 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
6 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dyne Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Legend Biotech's return on equity of -29.69% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -57.46% -51.62%
Legend Biotech -66.92%-29.69%-19.45%

Dyne Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500.

Summary

Dyne Therapeutics beats Legend Biotech on 12 of the 18 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DYN vs. The Competition

MetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.64B$6.88B$5.57B$8.50B
Dividend YieldN/A2.48%5.27%4.17%
P/E Ratio-4.058.4626.7519.66
Price / SalesN/A261.91403.98152.07
Price / CashN/A65.8538.2534.64
Price / Book9.676.526.964.59
Net Income-$235.94M$143.26M$3.23B$248.23M
7 Day Performance-1.97%-0.21%-1.22%-1.07%
1 Month Performance22.74%10.62%6.34%2.59%
1 Year Performance-56.43%3.63%33.05%13.50%

Dyne Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DYN
Dyne Therapeutics
2.4385 of 5 stars
$14.41
-0.3%
$44.93
+211.8%
-56.4%$1.64BN/A-4.05100Positive News
Analyst Forecast
Gap Down
LEGN
Legend Biotech
3.0816 of 5 stars
$34.78
-0.6%
$76.20
+119.1%
-13.2%$6.39B$728.30M-36.611,070Short Interest ↑
Analyst Revision
Gap Down
TGTX
TG Therapeutics
3.5298 of 5 stars
$39.84
-0.5%
$40.80
+2.4%
+117.6%$6.32B$386.39M-398.36290Positive News
Analyst Revision
Gap Down
GRFS
Grifols
3.5618 of 5 stars
$8.83
+0.1%
N/A+26.7%$6.07B$7.21B7.5526,300Gap Down
LNTH
Lantheus
4.3227 of 5 stars
$83.22
+2.0%
$132.67
+59.4%
-1.8%$5.76B$1.54B13.85700
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$16.91
+0.8%
$22.00
+30.1%
N/A$5.72B$783.21M0.00N/ANews Coverage
Analyst Forecast
Gap Down
NUVL
Nuvalent
2.3389 of 5 stars
$76.08
-2.5%
$115.50
+51.8%
+0.6%$5.46BN/A-21.9340
AXSM
Axsome Therapeutics
4.7308 of 5 stars
$109.87
-1.8%
$172.80
+57.3%
+41.4%$5.41B$432.16M-18.34380Trending News
Analyst Forecast
Insider Trade
Analyst Revision
ADMA
ADMA Biologics
2.3447 of 5 stars
$20.87
+1.3%
$24.25
+16.2%
+95.8%$4.98B$459.38M74.54530Positive News
Insider Trade
Analyst Revision
PCVX
Vaxcyte
3.161 of 5 stars
$37.20
+0.6%
$136.50
+266.9%
-52.6%$4.80BN/A-8.09160Positive News
Analyst Revision
Gap Down
AKRO
Akero Therapeutics
3.6098 of 5 stars
$54.71
+0.8%
$82.50
+50.8%
+131.9%$4.36BN/A-14.5930Trending News
Insider Trade
High Trading Volume

Related Companies and Tools


This page (NASDAQ:DYN) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners